Loading stock data…
$1.18-0.02 (-1.67%)
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
BioVie Inc. in the Healthcare sector is trading at $1.18 with a market capitalization of $16M. Wall Street consensus targets $5.25 (2 analysts), implying a +345.3% move over the next 12 months. The stock is currently near its 52-week low of $0.82, remaining 21.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.72M↓ | -$5.39M↑ | -$6.26M↓ | -$5.28M↓ | -$3.66M |
| Net Income | -$5.65M↓ | -$5.27M↑ | -$6.07M↓ | -$5.09M↓ | -$3.49M |
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment...